CNBC's Seema Moody reports on heightened interest in treating rare diseases as more patents expire. BioMarin Pharmaceutical is one of the leaders in this space, and its CEO Jean-Jacques Biename, weighs in.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT